SCHEMBL4101226

SCHEMBL4101226

Cc1cc(C)cc(N2C(=O)c3cccc4cccc(c34)C2=O)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.73
KDM4E B2RXH2 5/20 0.58
HPGD P15428 4/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
BRD1 O95696 2/20 0.56
HSD17B10 Q99714 3/20 0.54
GAA P10253 2/20 0.54
CA12 O43570 2/20 0.54
CA9 Q16790 2/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
MAPT P10636 2/20 0.54
MAPK1 P28482 1/20 0.54
HTT P42858 1/20 0.54
RXFP1 Q9HBX9 1/20 0.54
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
PSMD14 O00487 1/20 0.52
TP53 P04637 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28271625 0.84 ALDH1A1 (1.00) ALDH1A1KDM4EHPGDSMN1; SMN2MEN1
SCHEMBL30792888 0.83 GRM5 (0.62) ALDH1A1MEN1KMT2AHSD17B10
SCHEMBL5604859 0.83 GRM5 (0.62) ALDH1A1MEN1KMT2AHSD17B10
SCHEMBL27855153 0.82 ALDH1A1 (0.62) ALDH1A1KDM4EHPGDSMN1; SMN2MEN1
SCHEMBL20735193 0.81 ALDH1A1 (0.82) ALDH1A1KDM4EHPGDSMN1; SMN2MEN1
SCHEMBL16449728 0.79 KMT2A (0.82) ALDH1A1KDM4EHPGDSMN1; SMN2MEN1
SCHEMBL9290303 0.78 ALDH1A1 (0.47) ALDH1A1KDM4EHPGDSMN1; SMN2MEN1
SCHEMBL299841 0.78 ALDH1A1 (0.71) ALDH1A1KDM4EHPGDSMN1; SMN2MEN1
SCHEMBL10864719 0.78 PDE6D (0.58) ALDH1A1KDM4EHPGDSMN1; SMN2MEN1
SCHEMBL29354879 0.77 MEN1 (0.49) ALDH1A1KDM4EHPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109535767-B Preparation method of perylene pigment 江苏丽王科技股份有限公司 2023-08-04 CN claimed
US-20090215815-A1 Neurotrophin antagonist compositions PAINCEPTOR PHARMA CORPORATION (CA) 2009-08-27 US claimed
EP-0930883-B1 NEUROTROPHIN ANTAGONISTS FOR THE TREATMENT OF EPILEPSY, ALZHEIMER'S DISEASE AND PAIN ALLELIX BIOPHARMA (CA) 2006-01-11 EP claimed
US-20050250807-A1 Neurotrophin antagonist compositions TEHIM ASHOK 2005-11-10 US claimed
US-20020169182-A1 Neurotrophin antagonist compositions ALLELIX BIOPHARMACEUTICALS INC. (CA) 2002-11-14 US claimed
EP-0930883-A1 NEUROTROPHIN ANTAGONIST COMPOSITIONS Allelix Biopharmaceuticals Inc. (CA) 1999-07-28 EP claimed
WO-1998017278-A1 NEUROTROPHIN ANTAGONIST COMPOSITIONS ALLELIX BIOPHARMACEUTICALS INC. (CA) 1998-04-30 WO claimed
CN-109535767-B Preparation method of perylene pigment 江苏丽王科技股份有限公司 2023-08-04 CN disclosed
CN-109535767-A The preparation method of one germline pigment 江苏丽王科技股份有限公司 2019-03-29 CN disclosed
US-20090215815-A1 Neurotrophin antagonist compositions PAINCEPTOR PHARMA CORPORATION (CA) 2009-08-27 US disclosed
US-20080287484-A1 Neurotrophin antagonist compositions TEHIM ASHOK 2008-11-20 US disclosed
US-7291629-B2 Neurotrophin antagonist compositions PAINCEPTOR PHARMA CORPORATION (CA) 2007-11-06 US disclosed
EP-0930883-B1 NEUROTROPHIN ANTAGONISTS FOR THE TREATMENT OF EPILEPSY, ALZHEIMER'S DISEASE AND PAIN ALLELIX BIOPHARMA (CA) 2006-01-11 EP disclosed
US-20050250807-A1 Neurotrophin antagonist compositions TEHIM ASHOK 2005-11-10 US disclosed
US-20020169182-A1 Neurotrophin antagonist compositions ALLELIX BIOPHARMACEUTICALS INC. (CA) 2002-11-14 US disclosed
EP-0930883-A1 NEUROTROPHIN ANTAGONIST COMPOSITIONS Allelix Biopharmaceuticals Inc. (CA) 1999-07-28 EP disclosed
WO-1998017278-A1 NEUROTROPHIN ANTAGONIST COMPOSITIONS ALLELIX BIOPHARMACEUTICALS INC. (CA) 1998-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215815-A1 Neurotrophin antagonist compositions NGF, NTRK2, BDNF ALDH1A1 1561/4885KDM4E 2061/4885HPGD 1979/4885
US-20050250807-A1 Neurotrophin antagonist compositions NGF, NTRK2, BDNF ALDH1A1 1739/4885KDM4E 2261/4885HPGD 2042/4885
US-20020169182-A1 Neurotrophin antagonist compositions NTRK2, NGF, BDNF ALDH1A1 1523/4885KDM4E 3090/4885HPGD 1632/4885
US-20080287484-A1 Neurotrophin antagonist compositions NGF, NTRK2, BDNF ALDH1A1 1866/4885KDM4E 2031/4885HPGD 2079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.